Holen Sie sich die Stockscreener-App
16.40
9.25%
-1.6525
Schlusskurs vom Vortag:
$18.05
Offen:
$18.05
24-Stunden-Volumen:
981.06K
Relative Volume:
1.01
Marktkapitalisierung:
$800.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-695.98M
KGV:
-0.0499
EPS:
-328.6331
Netto-Cashflow:
$-143.65M
1W Leistung:
+11.43%
1M Leistung:
+8.33%
6M Leistung:
-54.10%
1J Leistung:
+44.42%
1-Tages-Spanne:
$16.23
$18.53
1-Wochen-Bereich:
$14.86
$19.70
52-Wochen-Spanne:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
16.39 | 881.70M | 0 | -695.98M | -143.65M | -328.63 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-09 | Eingeleitet | Citigroup | Buy |
| 2025-12-17 | Eingeleitet | TD Cowen | Buy |
| 2025-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-25 | Fortgesetzt | Wedbush | Neutral |
| 2025-10-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Vor Biopharma (VOR) upgraded to buy: Here's why - MSN
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Jefferies initiates coverage of Vor Biopharma (VOR) with buy recommendation - MSN
Vor Biopharma (VOR) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street experts anticipate that Vor Biopharma (VOR) could surge by 107.82%: Key Information You Need to Know - bitget.com
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Chen Yu and TCG entities hold 10.5% of Vor Biopharma (NASDAQ: VOR) - Stock Titan
TCG Crossover funds in Vor (VOR) disclose 2,836,539 common shares - Stock Titan
Vor Biopharma (VOR) ownership update shows RA Capital at 19.9% - Stock Titan
Vor Bio announces $75M private placement - MSN
Wedbush Maintains 'Neutral' Rating, Raises Price Target for Vor Biopharma (VOR) to $15 | VOR Stock News - gurufocus.com
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - MarketBeat
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What's behind the jump in Vor Biopharma stock? - MSN
Jefferies Initiates Coverage on Vor Biopharma (VOR) with a "Buy" Rating | VOR Stock News - gurufocus.com
Vor Biopharma, Inc. (VOR) PT Lowered to $48 at Jefferies - StreetInsider
Stifel cuts Vor Biopharma stock price target on financing assumptions - investing.com
Stifel cuts Vor Biopharma stock price target on financing assumptions By Investing.com - au.investing.com
Vor Biopharma, Inc. (VOR) PT Lowered to $40 at Stifel - StreetInsider
Vor Bio Announces $75 Million Private Placement with TCGX - marketscreener.com
Risk Check: What are Vor Biopharma Incs technical support levels2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Vor Bio Annual Report 2025: Telitacicept Global Development Strategy, Regulatory Overview, and Summary Risk Factors - Minichart
Jefferies Financial Group Initiates Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma Q4 profit tops estimates on warrant fair value gain - TradingView
Vor Biopharma (NASDAQ: VOR) secures $75M to fund autoimmune pipeline - Stock Titan
Vor 10-K: $696.0M Net Loss, Operating Expenses $371.6M; Cash Runway Into Early 2029 - TradingView
VOR: 2025 saw a $696M net loss, major restructuring, and a strategic shift to autoimmune therapies - TradingView
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Baird Upgrades Vor Biopharma (VOR) - MSN
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot - Investing.com Canada
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot By Investing.com - za.investing.com
Jefferies Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma Shares Climb 6.4% Premarket Aft - Moomoo
Vor Biopharma Announces $75 Million Private Placement Financing - TipRanks
What's Behind The Jump In Vor Biopharma Stock? - Benzinga
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Highe - Benzinga
Vor Biopharma Raises $75 Million in Private Placement With TCGX, Adds Registration Rights - TradingView
Vor Bio announces $75 million private placement with TCGX - marketscreener.com
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
Vor Biopharma Inc. announced that it expects to receive $74.999996 million in funding from TCG Crossover Management, LLC - marketscreener.com
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vor Biopharma Inc-Aktie (VOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):